<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02163837</url>
  </required_header>
  <id_info>
    <org_study_id>AK/14-02-14/4343</org_study_id>
    <nct_id>NCT02163837</nct_id>
  </id_info>
  <brief_title>Effect of Rifaximine on Sleep Disorders in Patients Suffering From Hepatic Encephalopathy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Saint Pierre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Saint Pierre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatic encephalopathy is responsible for sleep disturbances and daytime sleepiness. The
      purpose of our study is to assess sleep quality, quantity, sleep schemes and physical
      activity in patients suffering from HE, before and after a 2 weeks treatment with rifaximine,
      which is currently given to lower blood ammoniac levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatic encephalopathy (HE) is a complex neuropsychiatric syndrome related to chronic/acute
      hepatic failure. Sleep architecture is disturbed in this syndrome, and patients complain
      mainly of excessive daytime sleepiness and sleep disturbances. Hypothesis to explain these
      symptoms is, among others, disturbed melatonin metabolism. Few studies have been conducted in
      order to study sleep disorders during HE, and effect of treatment is unknown. Recently,
      rifaximine, an oral broad spectrum antibiotic, have been proved to decrease ammoniac
      production in patients with HE. The purpose of our study is to assess sleep quality,
      quantity, sleep schemes and physical activity in patients suffering from HE, before and after
      a 2 weeks treatment with rifaximine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Slow Wave Sleep and REM Sleep</measure>
    <time_frame>28 days</time_frame>
    <description>sum of percentage of sleep spent in slow wave sleep and REM sleep during sleep per 24h ; assessed by 24-h polysomnography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sleep Efficiency</measure>
    <time_frame>28 days</time_frame>
    <description>total sleep time/ time spent in bed per 24h, expressed in percentage of time spent in bed, assessed by actigraphy</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality of Sleep</measure>
    <time_frame>28 days</time_frame>
    <description>assessed by Pittsburgh sleep quality index questionnaire (PSQI). Values: 0 to 21. 21= worse sleep quality</description>
  </other_outcome>
  <other_outcome>
    <measure>Total Sleep Time</measure>
    <time_frame>28 days</time_frame>
    <description>total sleep time/ 24h, measured in minutes, by actigraphy</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Steps Walked Daily</measure>
    <time_frame>28 days</time_frame>
    <description>number of steps walked daily assessed by actigraphy (measure of physical activity)</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Hepatic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>rifaximine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rifaximine</intervention_name>
    <arm_group_label>rifaximine</arm_group_label>
    <other_name>Targaxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;18y hepatic encephalopathy: positive Conn score

        Exclusion Criteria:

          -  &lt;18y pregnancy inability to fulfil questionnaires acute infection unstable clinical
             condition bone or articular disease resulting in significant disability
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie Bruyneel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU St Pierre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU St Pierre</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>June 6, 2014</study_first_submitted>
  <study_first_submitted_qc>June 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2014</study_first_posted>
  <results_first_submitted>September 8, 2017</results_first_submitted>
  <results_first_submitted_qc>January 11, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 9, 2019</results_first_posted>
  <last_update_submitted>April 17, 2019</last_update_submitted>
  <last_update_submitted_qc>April 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire Saint Pierre</investigator_affiliation>
    <investigator_full_name>Marie Bruyneel</investigator_full_name>
    <investigator_title>Chef de clinique</investigator_title>
  </responsible_party>
  <keyword>sleep quality</keyword>
  <keyword>physical activity</keyword>
  <keyword>daytime sleepiness</keyword>
  <keyword>actigraphy</keyword>
  <keyword>quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatic Encephalopathy</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>all participants of this single arm study were actively enrolled</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Rifaximine</title>
          <description>rifaximine was given to all included patients after one week of assesment of sleep disturbances by polysomnography, actigraphy and questionnaires</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Before Rifaximin</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Day 28 of Rifaximin Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rifaximine</title>
          <description>rifaximine was given to all included patients after one week of assesment of sleep disturbances by polysomnography, actigraphy and questionnaires</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Slow Wave Sleep and REM Sleep</title>
        <description>sum of percentage of sleep spent in slow wave sleep and REM sleep during sleep per 24h ; assessed by 24-h polysomnography</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rifaximine</title>
            <description>rifaximine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Slow Wave Sleep and REM Sleep</title>
          <description>sum of percentage of sleep spent in slow wave sleep and REM sleep during sleep per 24h ; assessed by 24-h polysomnography</description>
          <units>percentage of total sleep time per 24h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Efficiency</title>
        <description>total sleep time/ time spent in bed per 24h, expressed in percentage of time spent in bed, assessed by actigraphy</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rifaximine</title>
            <description>rifaximine</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Efficiency</title>
          <description>total sleep time/ time spent in bed per 24h, expressed in percentage of time spent in bed, assessed by actigraphy</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Quality of Sleep</title>
        <description>assessed by Pittsburgh sleep quality index questionnaire (PSQI). Values: 0 to 21. 21= worse sleep quality</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rifaximine</title>
            <description>rifaximine</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Sleep</title>
          <description>assessed by Pittsburgh sleep quality index questionnaire (PSQI). Values: 0 to 21. 21= worse sleep quality</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Total Sleep Time</title>
        <description>total sleep time/ 24h, measured in minutes, by actigraphy</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rifaximine</title>
            <description>rifaximine</description>
          </group>
        </group_list>
        <measure>
          <title>Total Sleep Time</title>
          <description>total sleep time/ 24h, measured in minutes, by actigraphy</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="446" lower_limit="53" upper_limit="701"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Steps Walked Daily</title>
        <description>number of steps walked daily assessed by actigraphy (measure of physical activity)</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rifaximine</title>
            <description>rifaximine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Steps Walked Daily</title>
          <description>number of steps walked daily assessed by actigraphy (measure of physical activity)</description>
          <units>steps per day</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="905" lower_limit="56" upper_limit="5498"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Mc Nemar symetry test for repeated measures and paired t-tests as appropriated</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>the study was exploratory, the number of patients included was not calculated</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <method>McNemar</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Rifaximine</title>
          <description>rifaximine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Marie Bruyneel</name_or_title>
      <organization>Chu St Pierre</organization>
      <phone>003225354219</phone>
      <email>marie_bruyneel@stpierre-bru.be</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

